Catalent Agrees To Acquire Juniper Pharmaceuticals

Acquisition will strengthen Catalent's global early-phase development capabilities

Jefferson2

Nottingham, U.K.-based dose form development and clinical manufacturing specialist, Juniper will add a European Early Development Center of Excellence to Catalent’s global network. When combined with Catalent’s existing centers of excellence for early drug development in the U.S. and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings and will complement its integrated global clinical and commercial supply network.

Read full press release here.
Download more details here.

Juniper's commitment to science-based, solutions oriented development and to quality and operational excellence fits well with Catalent’s data-driven, consultative approach to early development. Catalent’s pharmaceutical customers will now be able to take advantage of accelerated and comprehensive clinical development and manufacturing capabilities at a location of their choice with seamless scale up to later clinical stages and commercial launch capabilities within Catalent's global network.

DissolvingMolecule_380x380

Learn more about Catalent’s Early-Phase Development Capabilities, including:

About Juniper Pharmaceuticals

A UK-based development partner focused on formulation and analytical development and early-phase clinical manufacturing of complex, small-molecule compounds, Juniper offers science-driven innovation and a portfolio of solutions to help customers reduce risk and accelerate their key drug development programs from discovery to the clinic. Offerings include:

Contact Us to find out about how we can help solve your development challenges.